Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: NOMOCAN PHARMACEUTICALS LLC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2023-02-27 to 2024-02-26
Current total value of award: $299959
Description: PC HAS ONE OF THE LOWEST 5-YEAR SURVIVAL RATES AMONG ALL CANCER TYPES, REMAINING BELOW 10% FOR THE PAST 40 YEARS, INDICATING A NEED FOR EFFECTIVE PC THERAPIES. STUDIES HAVE SHOWN THAT NMC-521 BINDS SELECTIVELY TO SEVERAL PC CELL LINES WITH MARKED ANT